



PharmaMar Group reports €45.5 million in revenues (+8%)

- **EBITDA was positive due to higher revenues and efficient cost management.**
- **The cash position reflects the receipt of the upfront payment under the agreement with Chugai Pharma signed in December.**

Madrid, 27th of April 2017: The PharmaMar Group (MSE:PHM) reported €45.5 million in total revenues in the first quarter of 2017, an 8% increase year-on-year. Yondelis[®] sales were stable in the period while Consumer Chemical sales rose 10% year-on-year. Revenues from royalties, licenses and other agreements amounted to €3.8 million in the first quarter. Of that figure, €2.2 million were from recognition of progress in the first quarter with the clinical trials envisaged in the lurbinectedin licensing agreement with Chugai Pharma Marketing.

Group Adjusted operating EBITDA amounted to €0.9 million in the first quarter of 2017, contrasting with -€3.9 million in the same period of 2016, due to higher revenues, efficient cost management, since Yondelis[®] distribution logistics were insourced, and a temporary decline in R&D expenditure since the Phase III pivotal trials under way in the first quarter of 2016 have concluded.

As a result, the Group reported -€2.5 million in net attributable income in the period, compared with -€7.1 million in the same period of 2016.

About PharmaMar

PharmaMar, a Madrid-based biopharmaceutical company, is a world leader in discovering, developing and marketing anti-tumour drugs obtained from the sea. PharmaMar has a rich pipeline of pre-clinical candidates and a major R&D programme. The company develops and markets YONDELIS[®] in Europe and has three other compounds in clinical development for treating solid and haematological tumours: plitidepsin, PM1183 and PM184. PharmaMar is a global biopharmaceutical company with a presence in Germany, Italy, France, Switzerland, the United Kingdom, Belgium and the USA. PharmaMar also has a



majority stake in other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, focused on developing therapeutic applications of gene silencing (RNAi); and two chemical companies: Zelnova Zeltia and Xylazel. For more information, visit our website: www.pharmamar.com

Important note

This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe for shares of the company. Moreover, no reliance should be placed upon this document or its distribution for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the Company.

Further information from:

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000



Investor relations:

José Luis Moreno Martínez-Losa – Head of Investor Relations and Capital Markets
investorrelations@pharmamar.com
Phone: +34 914444500
For more information, visit our website: www.pharmamar.com

###